Abstract
Objective:
There is emerging evidence that angiotensin stimulates adipocyte differentiation and lipogenesis. This study tested the hypothesis that inhibition of angiotensin II by treatment with an angiotensin-converting enzyme inhibitor, perindopril, would reduce fat mass in rats.
Design:
After a 12-day baseline, rats were divided into two groups: one was untreated and the other received perindopril (1.2 mg kg−1 per day) in drinking water for 26 days.
Subjects:
In total, 16 male Sprague–Dawley rats aged 10 weeks at the start of the study.
Measurements:
Plasma leptin was measured in samples collected at baseline, half-way through and at the end of treatment. Body weight, food and water intake were measured daily throughout the experiment. Body fat mass, bone and lean mass were determined by dual energy X-ray absorptiometry (DEXA) at the end of the treatment period.
Results:
Daily food intake was the same in both groups throughout the study. By the end of treatment, animals receiving perindopril showed a modest reduction in weight gain relative to the untreated animals (62.4±5.0 g vs 73.0±4.0 g; P<0.05). DEXA analysis showed that body composition was greatly altered and the perindopril-treated group had 26% less body fat mass than the untreated group (61.0±5.2 g vs 44.4±4.2 g; P<0.01). The reduction in body fat mass was correlated with reductions in the weight of both the epididymal and retroperitoneal fat pads (P<0.001). Similarly, plasma leptin was reduced by perindopril treatment (4.64±0.56 ng ml−1) compared to the untreated group (8.27±1.03 ng ml−1; P<0.001). In contrast, there were no differences in lean or bone mass between the two groups.
Conclusion:
Oral treatment with perindopril selectively reduced body fat mass without influencing daily food intake. In contrast, there were no differences in lean or bone mass between the two groups.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lafontan M, Viguerie N . Role of adipokines in the control of energy metabolism: focus on adiponectin. Curr Opin Pharmacol 2006; 6: 1–6.
Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsson LM . Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1988; 83: 3925–3929.
Schling P, Mallow H, Trindl A, Loffler G . Evidence for a local renin angiotensin system in primary cultured human preadipocytes. Int J Obes Relat Metab Disord 1999; 23: 336–341.
Engeli S, Negrel R, Sharma AM . Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000; 35: 1270–1277.
Cooper R, Forrester T, Ogunbiyi O, Muffinda J . Angiotensinogen levels and obesity in four black populations. ICSHIB Investigators. J Hypertens 1988; 16: 571–575.
Umemura S, Nyui N, Tamura K, Hibi K, Yamaguchi S, Nakamaru M et al. Plasma angiotensinogen concentrations in obese patients. Am J Hypertens 1997; 10: 629–633.
Cooper R, McFarlane-Anderson N, Bennett FI, Wilks R, Puras A, Tewksbury D et al. ACE, angiotensinogen and obesity: a potential pathway leading to hypertension. J Hum Hypertens 1997; 11: 107–111.
Licata G, Scaglione R, Ganguzza A, Corrao S, Donatelli M, Parrinello G et al. Central obesity and hypertension. Relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subjects. Am J Hypertens 1994; 7: 314–320.
van Harmelen V, Elizalde M, Ariapart P, Bergstedt-Lindqvist S, Reynisdottir S, Hoffstedt J et al. The association of human adipose angiotensinogen gene expression with abdominal fat distribution in obesity. Int J Obes Relat Metab Disord 2000; 24: 673–678.
Strazzullo P, Iacone R, Iacovello L, Russo O, Barba G, Russo P et al. Genetic variation in the renin-angiotensin system and abdominal adiposity in men: the Olivetti Prospective Heart Study. Ann Intern Med 2003; 17: 17–23.
Giacchetti G, Faloia E, Sardu C, Camilloni MA, Mariniello B, Gatti C et al. Gene expression of angiotensinogen in adipose tissue of obese patients. Int J Obes Relat Metab Disord 2000; 24 (Suppl 2): S142–S143.
Matsushita K, Wu Y, Okamoto Y, Pratt RE, Dzau VJ . Local renin-angiotensin system regulates human mesenchymal differentiation to adipocytes. Hypertension 2006; 48: 1095–1102.
Goossens GH, Blaak EE, Baak MA . Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev 2003; 4: 43–55.
Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM . Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002; 51: 1699–1707.
Jones BH, Standridge MK, Moustaid N . Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 1997; 138: 1512–1519.
Blaak EE, van Baak MA, Kemerink GJ, Pakbiers MT, Heidendal GA, Saris WH . Beta-adrenergic stimulation and abdominal subcutaneous fat blood flow in lean, obese, and reduced-obese subjects. Metabolism 1995; 44: 183–187.
Boschmann M, Ringel J, Klaus S, Sharma AM . Metabolic and hemodynamic response of adipose tissue to angiotensin II. Obes Res 2001; 9: 486–491.
Boschmann M, Engeli M, Adams F, Franke G, Luft FC, Sharma AM et al. Influence of AT-1 receptor blockade on tissue metabolism in obese men. Am J Physiol 2006; 290: R219–R223.
Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J et al. Long term angiotensin AT1 receptor inhibition induced adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPAR gamma. Eur J Pharmacol 2006; 552: 112–122.
Zanchi A, Dulloo AG, Perregaux C, Montani JP, Burnier M . Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitising properties. Am J Physiol Endocrinol Metab 2007; 293: E91–E95.
Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW . Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006; 47: 1003–1009.
Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M et al. PPAR-gamma activating angiotensin receptor type-1 blockers induce adiponectin. Hypertension 2005; 46: 137–143.
Shimabukuro M, Tanaka H, Shimabukuro T . Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hyperten 2007; 25: 841–848.
Massiera F, Seydoux J, Geloen A, Quignard-Boulange A, Turban S, Saint-Marc P et al. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 2001; 142: 5220–5225.
Kasper SO, Ferrario CM, Ganten D, Diz DI . Rats with low brain angiotensionogen do not exhibit insulin resistance during early aging. Endocr J 2006; 30: 167–174.
Brink M, Wellen J, Delafontaine P . Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest 1996; 97: 2509–2516.
Cassis LA, Marshall DE, Fettinger MJ, Rosenbluth B, Lodder RA . Mechanisms contributing to angiotensin II regulation of body weight. Am J Physiol 1998; 274: E867–E876.
Heimann AS, Favarato MH, Gozzo FC, Rioli V, Carreno FR, Eberlin MN et al. ACE gene titration in mice uncovers a new mechanism on the control of body weight. Physiol Genomics 2005; 20: 173–182.
Frederich RC, Hamann A, Anderson S, Lollmann B, Lowell BB, Flier JS . Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1995; 1: 1311–1314.
Dagogo-Jack S, Fanelli C, Paramore D, Brothers J, Landt M . Plasma leptin and insulin relationships in obese and nonobese humans. Diabetes 1996; 45: 695–698.
Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995; 1: 1155–1161.
Velkoska E, Morris MJ, Burns P, Weisinger RS . Leptin reduces food intake but does not alter weight regain following food deprivation in the rat. Int J Obes Relat Metab Disord 2003; 27: 48–54.
Pritchard JE, Nowson CA, Strauss BJ, Carlson JS, Kaymakci B, Wark JD . Evaluation of dual energy X-ray absorptiometry as a method of measurement of body fat. Eur J Clin Nutr 1993; 47: 216–228.
Jecquier E . Leptin signaling, adiposity and energy balance. Ann NY Acad Sci 2002; 967: 379–388.
Weisinger RS, Denton DA, Di Nicolantonio R, McKinley MJ . The effect of captopril or enalaprilic acid on Na-deplete rats. Clin Exp Physiol Pharmacol 1988; 15: 55–65.
Sakaguchi K, Chai SY, Jackson B, Johnston CI, Mendelsohn FA . Differential angiotensin-converting enzyme inhibition in brain after oral administration of perindopril demonstrated by quantitative in vitro autoradiography. Neuroendocrinology 1988; 48: 223–228.
Thunhorst RL, Xu Z, Cicha MZ, Zardetto-Smith AM, Johnson AK . Fos expression in rat brain during depletion-induced thirst and salt appetite. Am J Physiol 1998; 274: R1807–R1814.
Gilliam-Davis S, Payne VS, Kasper SO, Tommasi EN, Robbins ME, Diz DI . Long-term AT1 receptor blockade improves metabolic function and provides renoprotection in Fischer 344 rats. Am J Physiol 2007; 293: H1327–H1333.
Mifsud SA, Skinner SL, Cooper ME, Kelly DJ, Wilkinson-Berka JL . Effects of low-dose and early versus late perindopril treatment on the progression of severe diabetic nephropathy in (mREN-2)27 rats. J Am Soc Nephrol 2002; 13: 684–692.
Morrison CD, White CL, Wang Z, Lee SY, Lawrence DS, Cefalu WT et al. Increased hypothalamic protein tyrosine phosphatase 1b contributes to leptin resistance with age. Endocrinology 2007; 148: 433–440.
Weisinger HS, Begg DP, Egan GF, Jayasooriya AP, Lie F, Mathai ML et al. Angiotensin converting enzyme inhibition from birth reduces body weight and body fat in Sprague–Dawley rats. Physiol Behav 2008; 93: 820–825.
Santos EL, Souza KD, Guimaraes PB, Reis FCG, Silva SMA, Costa-Neto CM et al. Effect of angiotensin converting enzyme inhibitor enalapril on body weight and composition in young rats. Int Immunopharmacol 2008; 8: 247–253.
Carter CS, Onder G, Kritchevsky SB, Pahor M . Angiotensin-converting enzyme inhibition, body composition and physical performance in aged rats. J Gerontol A Biol Sci Med Sci 2005; 60: 1437–1446.
Jayasooriya AP, Mathai ML, Walker LL, Begg DP, Denton DA, Cameron-Smith D et al. Mice lacking angiotensin converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci (USA) 2008; 105: 6531–6536.
Fruebis J, Tsao TS, Javorschi S, Ebets-Reed D, Erickson MR, Yen FT et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci (USA) 2001; 98: 2005–2010.
Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S et al. Molecular activation of PPAR-gamma by angiotensin type-1 receptor antagonists. Vascular Pharmacol 2006; 45: 154–162.
Enalapril in Hypertension Study Group (UK). Enalapril in essential hypertension: a comparative study with propranolol. Br J Clin Pharmacol 1984; 18: 51–56.
Masuo K, Mikami H, Ogihara T, Tuck ML . Weight reduction and pharmacologic treatment in obese hypertensives. Am J Hypertens 2001; 14: 530–538.
Dixon JB, Strauss BJG, Laurie C, O'Brien PE . Changes in body composition with weight Loss: obese subjects randomized to surgical and medical programs. Obesity 2007; 15: 1187–1198.
Acknowledgements
MLM was supported by the G. Harald and Leila Y Mathers Charitable Foundation and the J Robert Jr and Helen C Kleberg Foundation. The support of grants from the Australia Research Council (DP0346830) and National Health and Medical Research Council (350313) is also gratefully acknowledged.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mathai, M., Naik, S., Sinclair, A. et al. Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats. Int J Obes 32, 1576–1584 (2008). https://doi.org/10.1038/ijo.2008.126
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ijo.2008.126
Keywords
This article is cited by
-
Telmisartan and candesartan promote browning of white adipose tissue and reverse fatty liver changes in high fat diet fed male albino rats
Naunyn-Schmiedeberg's Archives of Pharmacology (2024)
-
Dietary Sodium Suppresses Digestive Efficiency via the Renin-Angiotensin System
Scientific Reports (2015)
-
Relationship Between Aldosterone and Parathyroid Hormone, and the Effect of Angiotensin and Aldosterone Inhibition on Bone Health
Clinical Reviews in Bone and Mineral Metabolism (2015)
-
Control of Energy Balance by the Brain Renin-Angiotensin System
Current Hypertension Reports (2015)
-
Are we being drowned in hydration advice? Thirsty for more?
Extreme Physiology & Medicine (2014)